Breaking News Instant updates and real-time market news.

DISCA

Discovery

$26.80

0.41 (1.55%)

, SNI

Scripps Networks

$86.91

0.5 (0.58%)

12:27
07/31/17
07/31
12:27
07/31/17
12:27

On The Fly: Top stock stories at midday

Stocks began the session in positive territory, led by the Dow, which hit another new all-time high. The Nasdaq gave up its early gains and spent most of the morning trying to remain close to the flat line. Oil prices moved above $50 a barrel early in the day but were unable to hold that level and have since lost roughly 1% to slide back to near $49. ECONOMIC EVENTS: In the U.S., the Chicago PMI dropped 6.8 points to 58.9 in July, more than giving back its 6.3 point jump to 65.7 in June. The pending home sales index bounced 1.5% to 110.2 in June, which was better than expected. The Dallas Fed manufacturing index rose 1.8 points to 16.8 in July. In Asia, China's official government reading of its manufacturing PMI came in at 51.4, which was down from 51.7 in June, and the NBS services PMI slipped to 54.5 from 54.9 in June. Also, the Bank of Japan said it will keep its August bond purchase plans unchanged from July. In Europe, the flash estimate of the consumer price index for the euro area remained steady at 1.3% growth in July. Core inflation, excluding food and energy prices, rose to 1.2% in July. COMPANY NEWS: As recently telegraphed in media reports, Discovery Communications (DISCA) announced this morning that the company agreed to acquire Scripps Networks Interactive (SNI) in a cash-and-stock transaction valued at $14.6B, or $90 per Scripps share. Discovery also reported lower than expected earnings and revenue for the second quarter. The stock slid over 8% following the deal announcement, while Scripps, which also warned about a Q2 revenue shortfall and cut its full year revenue outlook, advanced 0.5% to about $87.50 per share near noon... Also in the media space, The Wall Street Journal reported over the weekend that Sprint (S) has proposed a merger with Charter Communications (CHTR). Charter met the report head on, announcing that while it understands "why a deal is attractive for SoftBank (SFTBF)...Charter has no interest in acquiring Sprint." SoftBank's Masayoshi Son, also the chairman of Sprint, may still decide to make a formal offer to acquire Charter anyway, a person familiar with the matter told the Journal. MAJOR MOVERS: Among the notable gainers was Dynavax (DVAX), which jumped 75% after the company announced that an FDA advisory committee voted 12 to 1 that the safety data for Heplisav-B support licensure for immunization against hepatitis B infection in adults 18 years of age and older. Also higher was Bristol-Myers (BMY), which gained 3% after announcing a clinical collaboration agreement to evaluate the combination of the company's immunotherapy Opdivo and Clovis' (CLVS) "PARP inhibitor" Rubraca in phase 3 cancer trials. Clovis shares, however, fell 11% following the partnership announcement, as investors betting on a takeover may have been disappointed that this deal could lower the chances of such a sale. Also lower was Hertz (HTZ), which fell 16% after Barclays downgraded the shares to Underweight, with analyst Brian Johnson arguing that the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since late June. Additionally, in a regulatory filing out late Friday night, Hertz disclosed that it will not be able to move forward with its prior notice to redeem $450M of outstanding debt. INDEXES: Near midday, the Dow was up 81.82, or 0.37%, to 21,912.13, the Nasdaq was down 18.40, or 0.29%, to 6,356.27, and the S&P 500 was up 0.46, or 0.02%, to 2,472.56.

DISCA

Discovery

$26.80

0.41 (1.55%)

SNI

Scripps Networks

$86.91

0.5 (0.58%)

CHTR

Charter

$370.26

3.36 (0.92%)

S

Sprint

$7.97

-0.25 (-3.04%)

SFTBF

SoftBank

$83.10

-0.3825 (-0.46%)

BMY

Bristol-Myers

$57.01

1.735 (3.14%)

CLVS

Clovis

$98.02

5.77 (6.25%)

DVAX

Dynavax

HTZ

Hertz

$14.64

-2.7008 (-15.58%)

  • 31

    Jul

  • 31

    Jul

  • 31

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 10

    Aug

  • 14

    Aug

  • 11

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

DISCA Discovery
$26.80

0.41 (1.55%)

07/31/17
LOOP
07/31/17
NO CHANGE
LOOP
Hold
Discovery deal accretion not enough to get 'overly excited,' says Loop Capital
Loop Capital analyst David Miller said that Discovery's (DISCA) agreement to acquire Scripps Networks (SNI) is accretive, but not enough to get him "overly excited." Miller, who views the well-telegraphed deal as more "playing defense" than anything else, keeps a Hold rating on Discovery shares.
07/26/17
WELS
07/26/17
NO CHANGE
WELS
Scripps Networks could be acquired for $91-$95 per share, says Wells Fargo
After the Wall Street Journal reported that Discovery (DISCA) and Viacom (VIAB) are interested in buying Scripps' (SNI) assets, Wells Fargo estimates that Scripps could be acquired for $91-$95 per share. The firm believes that the acquirer or acquirers could realize a total of about $175M of non-programming expense synergies. It keeps a Market Perform rating on Scripps.
07/25/17
NEED
07/25/17
NO CHANGE
NEED
Hold
Needham likes Scripps Networks best as Discovery merger partner
Needham analyst Laura Martin believes Discovery (DISCA) will decide to protect its U.S. asset value rather than exit, and likes Scripps Networks (SNI) best as a merger partner for the company. The analyst reiterates a Hold rating on Discovery's shares.
07/20/17
07/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Citi. 2. Johnson & Johnson (JNJ) reinstated with an Outperform at Credit Suisse. 3. Tile Shop (TTS) initiated with a Hold at Loop Capital. 4. Spring Bank Pharmaceuticals (SBPH) initiated with an Overweight at Cantor. 5. Discovery (DISCA) and Scripps Networks (SNI) were initiated with a Market Perform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SNI Scripps Networks
$86.91

0.5 (0.58%)

CHTR Charter
$370.26

3.36 (0.92%)

06/08/17
MOFT
06/08/17
NO CHANGE
MOFT
Charter spectrum values likely falling, says MoffettNathanson
MoffettNathanson said spectrum values are likely falling rather than rising, and investors are likely overestimating what buyers are willing to pay, a negative for current spectrum owners. The firm's analyst said Charter is likely a long-term acquirer, but near-term acquisitions are unlikely given the integrations of Time Warner Cable and Bright House.
06/01/17
OPCO
06/01/17
INITIATION
OPCO
Perform
Charter initiated with a Perform at Oppenheimer
Oppenheimer analyst Timothy Horan initiated Charter with a Perform rating saying free cash flow growth is reflected in valuation.
06/27/17
JEFF
06/27/17
NO CHANGE
JEFF
Jefferies sees Sprint takeover by Comcast, Charter as less likely
Jefferies analyst Mike McCormack says this morning's Wall Street Journal report exclusive talks between Sprint (S) and Comcast (CMCSA)/Charter (CHTR) is not surprising. He believes the cable operators are looking for better MVNO terms and that an outright acquisition or equity stake is less likely. The report provides an indication of just how far apart Sprint and T-Mobile (TMUS) may be in any discussions, McCormack tells investors in a research note. The exclusive talks may also push T-Mobile closer to DISH (DISH), the analyst adds.
07/31/17
JPMS
07/31/17
NO CHANGE
Target $450
JPMS
Overweight
Charter offer would likely have to be at least $500 per share, says JPMorgan
JPMorgan analyst Philip Cusick believes SoftBank (SFTBY) is one of the few companies that could offer a big enough price to take control of Charter Communications (CHTR). While a deal is not very likely, Softbank Chairman Masayoshi Son "is never to be counted out as a buyer," Cusick tells investors in a research note. He believes a Charter acquisition offer would likely have to be in the $500 per share or higher range. Charter shares in premarket trading are up $31.74 to $402 after the Wall Street Journal reported Friday night that SoftBank has interest in merging the company with Sprint. Cusick estimates annual synergies between Sprint (S) and Charter could be around $2B, with minimal cost to integrate versus a Sprint and T-Mobile (TMUS) merger "which would have more eventual cost savings but cost much more to integrate." A Sprint and Charter deal would not have a difficult regulatory review, the analyst believes. Cusick adds that if Charter looked like it was going to sell to Softbank, Comcast (CMCSA) would have to decide if it ever did want to buy Charter and "move more quickly with an even bigger premium."
S Sprint
$7.97

-0.25 (-3.04%)

05/30/17
MOFT
05/30/17
NO CHANGE
MOFT
U.S. telecom sector upgraded to Neutral from Sell at MoffettNathanson
MoffettNathanson analyst Craig Moffett upgraded the U.S. telecom sector to Neutral from Sell. As reasons for the upgrade, the analyst cited valuation, lack of near-term negative catalysts, interest rate easing, and a potential merger between Sprint (S) and T-Mobile (TMUS). Other stocks in the sector include Verizon (VZ) and AT&T (T). The firm today upgraded AT&T to Neutral from Sell.
05/30/17
BTIG
05/30/17
NO CHANGE
BTIG
Verizon shares could rise to $51 but outlook still mixed, says BTIG
BTIg analyst Walter Piecyk believes that Verizon's (VZ) stock can rise to $51. He notes that the company's wireless "margins and churn are still near record levels," while Sprint's (S) CEO expects prices for unlimited data plans to rise. Additionally, the analyst believes that the chances of Verizon making "a large dilutive acquisition" have decreased, while Verizon would benefit from a merger of Sprint and T-Mobile (TMUS). However, the analyst lowered his estimates for Verizon ,and he thinks that the company's dividend could be at risk over the longer term. Moreover, he warns that the stock could come under pressure if the T-Mobile/Sprint merger falls through, while a new , "well-funded" competitor could enter the wireless space. He keeps a Neutral rating on Verizon.
SFTBF SoftBank
$83.10

-0.3825 (-0.46%)

08/23/16
JPMS
08/23/16
UPGRADE
JPMS
Overweight
SoftBank upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jun Tanabe upgraded SoftBank (SFTBF) to Overweight from Neutral and raised his price target on the stock to Y9,930 from Y6,500, citing improved earnings at Sprint (S), the growth in value of its stake in Alibaba (BABA), and the stability of cash flow in its domestic mobile business.
08/23/16
08/23/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he now feels more confident in the company's growth and profitability outlook and its competitive position following three quarters of consistent execution. 2. BHP Billiton (BHP) upgraded to Buy from Hold at Jefferies with analyst Christopher LaFemina saying he believes fundamentals have "clearly improved," citing supply that has declined in most cases and demand that has stabilized. 3. SoftBank (SFTBF) upgraded to Overweight from Neutral at JPMorgan with analyst Jun Tanabe citing improved earnings at Sprint (S), the growth in value of its stake in Alibaba (BABA), and the stability of cash flow in its domestic mobile business. 4. Allscripts (MDRX) upgraded to Outperform from Market Perform at Leerink with analyst David Larsen saying he believes that the company's core fundamentals are improving "significantly." 5. Westlake Chemical (WLK) upgraded to Outperform from Sector Perform at RBC Capital with analyst Arun Viswanathan saying that the company's merger with Axiall (AXLL) "creates a new way to play chlor-alkali," as well as synergies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/16
OPCO
12/07/16
NO CHANGE
Target $70
OPCO
Outperform
T-Mobile price target raised to $70 from $55 at Oppenheimer
Oppenheimer analyst Timothy Horan raised his price target for T-Mobile (TMUS) to $70 from $55 as he views it as the best way to play the deregulatory/technology driven consolidation. The analyst notes that President-Elect Trump met with Masayoshi Son of SoftBank (SFTBF), who agreed to invest $50B in the U.S. Horan believes the meeting will likely be a precursor to a Sprint (S)/T-Mobile/Dish (DISH) merger to create a discounted quad-play service company. The analyst reiterates an Outperform rating on T-Mobile' shares, and points out that the company has improved its network and taken share from AT&T (T)/Verizon (VZ).
BMY Bristol-Myers
$57.01

1.735 (3.14%)

07/31/17
JANY
07/31/17
NO CHANGE
Target $107
JANY
Buy
Clovis partnership undercuts takeover thesis, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay says Clovis Oncology's (CLVS) clinical partnership with Bristol-Myer Squibb (BMY) undercuts his takeout thesis. The recent agreements across the PARP drugs implies no near-term takeovers, Chattopadhyay tells investors in a research note. He believes this will "likely to be disappointing to many." The analyst has a Buy rating on Clovis with a $107 price target. The shares in early trading are down $8.04, or 8% to $89.97.
07/27/17
LEER
07/27/17
NO CHANGE
LEER
Outperform
AstraZeneca trial failure negative for Bristol-Myers, says Leerink
Leerink analyst Seamus Fernandez notes that AstraZeneca (AZN) announced that the MYSTIC trial failed to show a progression-free survival benefit for Imfinzi + tremelimumab compared to chemotherapy in first-line non-small cell lung cancer patients with PDL1 expression greater than 25%. The read through is an obvious negative readthrough for Bristol-Myers' (BMY) combo of Opdivo + Yervoy in the ongoing CheckMate-227 trial, the analyst says. He points out that while there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes. Fernandez reiterates an Outperform rating on Bristol-Myers' shares.
07/28/17
LEER
07/28/17
NO CHANGE
Target $61
LEER
Outperform
Bristol-Myers price target lowered to $61 after Astra trial setback at Leerink
Leerink analyst Seamus Fernandez said Bristol-Myers (BMY) reported "solid" Q2 results, including encouraging growth for its key franchises, but he sees increased uncertainty following the failure of AstraZeneca's (AZN) MYSTIC trial, which has potential read through to Bristol's CheckMate-227 trial of its I/O combo of Opdivo + Yervoy. Fernandez lowered his price target on Bristol shares to $61 from $66, but "fully acknowledges" the range of differences in the trial designs. He keeps an Outperform rating on Bristol-Myers, citing prospects for monotherapy Opdivo approval in the second-line setting and success in first-line liver cancer.
07/31/17
LEER
07/31/17
NO CHANGE
LEER
Outperform
Clovis weakness unwarranted after Bristol-Myers pact, says Leerink
Leerink analyst Michael Schmidt thinks today's weakness in Clovis (CLVS) is unwarranted following the company's clinical collaboration agreement with Bristol-Myers (BMY) and presents a buying opportunity. This deal does not preclude a future acquisition of the company, but it does increase the competitiveness and value of Rubraca, argues Schmidt, who reiterates his Outperform rating on Clovis shares.
CLVS Clovis
$98.02

5.77 (6.25%)

07/31/17
JPMS
07/31/17
NO CHANGE
JPMS
Clovis takeover thesis not off the table, says JPMorgan
JPMorgan said the Clovis (CLVS) and Bristol-Myers (BMY) collaboration does not impact the takeover thesis of Clovis. Analyst Cory Kasimov said the the no-strings-attached clinical collaboration has no financial terms aside from provision of study drug and sharing of trial costs in some instances and Bristol does not have first rights of refusal if an interested party did approach Clovis.
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
DVAX Dynavax

07/31/17
RBCM
07/31/17
UPGRADE
RBCM
Outperform
Dynavax upgraded to Outperform from Sector Perform at RBC Capital
07/31/17
WBLR
07/31/17
NO CHANGE
WBLR
Outperform
Dynavax fair value estimate raised to $30 from $17 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate for Dynavax shares to $30 after an FDA panel voted 12-1 that the safety to date supports Heplisav approval for vaccination against hepatitis B infection in adults over 18 years old. The analyst believes the vote will lead to approval of Heplisav on its FDA action date of August 10. Dynavax's oncology candidates, if successful, could generate higher value than Heplisav for the shares, Xu tells investors in a research note. She keeps an Outperform rating on the name.
07/31/17
JPMS
07/31/17
UPGRADE
Target $27
JPMS
Overweight
Dynavax upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Dynavax to Overweight and raised his price target for the shares to $27 from $6. Following last week's FDA panel, the analyst now believes that hepatitis B vaccine Heplisav has a high probability of approval by the August 10 action date. He expects "rapid uptake" and sees $450M-plus in peak sales in the U.S. alone. Further, Rama believes SD-101 has compelling early-stage data in treatment-naive melanoma. The analyst views the asset as underappreciated.
07/31/17
RBCM
07/31/17
UPGRADE
RBCM
Outperform
Dynavax upgraded on positive FDA panel at RBC Capital
As noted earlier, RBC Capital upgraded Dynavax to Outperform from Sector Perform. Analyst Matthew Eckler says that a positive report from an FDA panel on the company's HEPLISAV-B vaccine significantly lowers the vaccine's risk and could cause investors to become interested in the stock again. The analyst is upbeat on the vaccine's outlook and raised his price target on the shares to $26 from $7.
HTZ Hertz
$14.64

-2.7008 (-15.58%)

06/14/17
DBAB
06/14/17
NO CHANGE
Target $45
DBAB
Buy
Avis Budget negative sentiment could be easing, says Deutsche Bank
Deutsche Bank analyst Chris Woronka attributes yesterday's rally in Avis Budget (CAR) shares to J.D. Power announcing a 270 basis point positive revision, from down 10.3% to down 7.6%, to the NADA used vehicle price index for June that it initially released late Monday. The rally implies that the "overwhelmingly" negative sentiment on Avis "could be showing signs of easing," Woronka tells investors in a research note. The analyst continues to view the Manheim used vehicle value index as the single most relevant data point for the shares. He believes July is a critical month for rental price and keeps a Buy rating on Avis with a $45 price target. Hertz (HTZ) yesterday followed shares of Avis higher.
07/31/17
07/31/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Sell from Hold at Pivotal Research with analyst Brian Wieser saying the shares are not factoring in risks to the company's growth following their "remarkable run" this year. 2. Ulta Beauty (ULTA) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh saying softer commentary from L'Oreal on its earnings call, increasing promotional activity from the department store channel, and more difficult year-over-year comparisons "could now signal a potentially more challenging beauty backdrop going forward." 3. Hertz (HTZ) downgraded to Underweight from Equal Weight at Barclays with analyst Brian Johnson saying fundamentals may have bottomed, but the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since June 21. 4. Citi (C) downgraded to Market Perform from Outperform at BMO Capital with analyst James Fotheringham citing valuation and lack of catalysts. 5. Visteon (VC) downgraded to Neutral from Buy at UBS with analyst Colin Langan saying the risk/reward is more balanced with the shares up 60% over the last year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/17
LEHM
07/31/17
DOWNGRADE
Target $9
LEHM
Underweight
Hertz downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Brian Johnson downgraded Hertz Global Holdings to Underweight with an unchanged price target of $9. Fundamentals may have bottomed, but the stock is ignoring the challenges ahead in the company's earnings recovery following the nearly 100% rally since June 21, Johnson tells investors in a research note. He expects a "sharp miss" relative to expectations when Hertz reports Q2 results.
06/27/17
MKMP
06/27/17
NO CHANGE
MKMP
Autonomous vehicle deals positive for car rental companies, says MKM Partners
After Avis (CAR) announced a multi-year deal with on autonomous vehicles with Alphabet's (GOOG, GOOGL) Waymo and news reports stated that Hertz (HTZ) is working with Apple (AAPL) on autonomous vehicles, MKM Partners analyst Christopher Agnew says the news should ease investors' concerns about car rental companies no longer existing in five to ten years. The analyst believes that car rental companies will become "more relevant" following the launch of autonomous vehicles due to their fleet management skills. He keeps Buy ratings on Hertz and Avis.

TODAY'S FREE FLY STORIES

10:30
11/23/17
11/23
10:30
11/23/17
10:30
General news
FX Action: EUR-USD, USD-JPY and other major pairings are in sideways mode »

FX Action: EUR-USD,…

DE

Deere

$145.25

6.02 (4.32%)

09:53
11/23/17
11/23
09:53
11/23/17
09:53
Upgrade
Deutsche Bank gets off sidelines, upgrades Deere shares to Buy »

Deutsche Bank analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

08:55
11/23/17
11/23
08:55
11/23/17
08:55
General news
FX Update: USD-CAD vaulted upwards on weak Canadian data »

FX Update: USD-CAD…

08:30
11/23/17
11/23
08:30
11/23/17
08:30
General news
FX Action: The USD index (DXY) logged a one-month low »

FX Action: The USD index…

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:08
11/23/17
11/23
08:08
11/23/17
08:08
Hot Stocks
Tesla CEO highlights 'record time' on Australian ion battery »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:07
11/23/17
11/23
08:07
11/23/17
08:07
Hot Stocks
Tesla completes construction on largest lithium ion battery in Australia »

The South Australian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

, INVA

Innoviva

$13.42

0.01 (0.07%)

07:56
11/23/17
11/23
07:56
11/23/17
07:56
Hot Stocks
GSK, Innoviva submit data to FDA for expanded Trelegy Ellipta label »

GlaxoSmithKline (GSK) and…

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

INVA

Innoviva

$13.42

0.01 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVM

Silvercorp Metals

$2.51

-0.07 (-2.71%)

07:52
11/23/17
11/23
07:52
11/23/17
07:52
Hot Stocks
Silvercorp Metals to buy back up to 5% of shares »

Silvercorp Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$10.00

-0.1 (-0.99%)

07:49
11/23/17
11/23
07:49
11/23/17
07:49
Hot Stocks
Cellcom Israel now second layer company according to Concentration Law »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GASS

StealthGas

$4.07

0.36 (9.70%)

07:06
11/23/17
11/23
07:06
11/23/17
07:06
Recommendations
StealthGas analyst commentary at Jefferies »

StealthGas trades at only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$41.01

4.31 (11.74%)

07:02
11/23/17
11/23
07:02
11/23/17
07:02
Recommendations
Copart analyst commentary at Jefferies »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DE

Deere

$145.25

6.02 (4.32%)

06:56
11/23/17
11/23
06:56
11/23/17
06:56
Upgrade
Deere rating change at Deutsche Bank »

Deere upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DE

Deere

$145.25

6.02 (4.32%)

06:55
11/23/17
11/23
06:55
11/23/17
06:55
Recommendations
Deere analyst commentary at Wells Fargo »

Deere price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

06:40
11/23/17
11/23
06:40
11/23/17
06:40
General news
FX Update: The dollar has remained on a weakening track »

FX Update: The dollar has…

SECO

Seeco Holding

$8.34

0.14 (1.71%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Seeco Holding management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Deutsche Bank to hold a conference »

Thailand SET Corporate…

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

04:25
11/23/17
11/23
04:25
11/23/17
04:25
General news
FX Action: USD-CAD punched out a 10-day low »

FX Action: USD-CAD…

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.